This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): 4SC-205
Description: 4SC-205 is an oral, small molecule Eg5 kinesin inhibitor which is required for mitosis. Unlike taxol, which directly binds to and stabilizes microtubules, which is neurotoxic, 4SC-203 only interacts with Eg5 which is only present during cell division.
Eg5 is a kinesin motor protein that mediates the segregation of the two spindle poles. Inhibition of Eg5 leads to cell cycle arrest in mitosis and subsequent programmed cell death (apoptosis).
4SC and Link Health
In May 2016, 4SC has entered into a licensing and development partnership for the cancer compound 4SC-205 with Guangzhou LingSheng Pharma Tech (Link Health). Link Health will receive the exclusive licensing rights for the development and marketing of 4SC-205 in China, Hong Kong, Taiwan and Macao. In return, Link Health will be responsible for performing and financing the clinical development of 4SC-205. After completing the clinical studies, Link Health will be responsible for regulatory approval at the CFDA (China Food and Drug Administration) and regional product marketing.
Under the agreement, 4SC will receive upfront and milestone payments totaling up to EUR 76 million from Link Health payable upon achieving specified development, regulatory and commercialization milestones. In addition, 4SC will be eligible to double-digit royalties linked to product sales of 4SC-205 in China.
Partners: Link Health Group
Additional information available to subscribers only: